

# ASX ANNOUNCEMENT

22 July 2025



## Appendix 3Y – Covering Letter

Little Green Pharma Ltd (ASX:LGP) ("**LGP**" or the "**Company**") wishes to advise of the following in relation to the attached Appendix 3Y Change in Director Interest Notices ("**Notices**") for Directors, Mr Michael Lynch-Bell and Dr Neale Fong.



The Notices have been prepared to reflect the change in securities held by Mr Lynch-Bell and Dr Fong on 15 July 2025 (refer to detail contained in the attached Notices). In the process of preparing these Notices, the Company became aware that previous changes in the interests of Mr Lynch-Bell and Dr Fong had not been disclosed via Appendix 3Y Change in Director Interest Notices. The details of these changes that have not been disclosed are as follows:

- On 22 July 2024, the Company announced the cancellation of unlisted options exercisable at \$0.25 expiring 19 July 2024. Mr Lynch-Bell held 250,000 securities in this class and Dr Neale Fong held 125,000 securities in this class.
- On 25 November 2024, the Company announced the issue of Retention Share Rights vesting 31 March 2027 and expiring 31 March 2029. Mr Lynch-Bell was issued 300,000 securities in this class and Dr Neale Fong was issued 150,000 securities in this class pursuant to shareholder approval received at the Company's AGM held on 29 August 2024.

The Company has taken the above changes into account in preparing the attached Notices. The Company confirms the following:

- The non-disclosure of the above changes in securities for Directors, Mr Lynch-Bell and Dr Fong were due to an administrative oversight. As soon as the oversights were identified whilst preparing the attached Notices, this covering announcement was prepared and lodged with ASX.
- The Company is satisfied that it has the necessary reporting and notification practices in place to ensure compliance with its disclosure requirements under ASX Listing Rule 3.19A and 3.19B.
- The Company considers that the late lodgment is an isolated incident. Further, the Company believes that its current practices are adequate to ensure compliance with the ASX Listing Rules.

**ENDS**

**BY ORDER OF THE COMPANY SECRETARY**

A handwritten signature in black ink, appearing to read "Alistair Warren".

**Alistair Warren**  
Company Secretary

For further information please contact:

**Alistair Warren**  
**Company Secretary**

Little Green Pharma  
E: [cosec@lgp.global](mailto:cosec@lgp.global)  
T: +61 8 6280 0050

**Paul Long**  
**Managing Director**

Little Green Pharma  
E: [p.long@lgp.global](mailto:p.long@lgp.global)  
T: +61 8 6280 0050



## About Little Green Pharma

Little Green Pharma Ltd (ASX:LGP) is a leading global medicinal cannabis company with vertically integrated operations across Europe and Australia.

LGP has a diverse and growing portfolio of cannabis-based medicines, distributed across Australia and over 12 export markets via a network of wholesalers, pharmacies, clinics, and GPs. The Company generates revenue through both the sale of medicinal cannabis products and its domestic Health House distribution business, which allows it to capture value across the supply chain and to adapt to evolving regulatory environments while building defensible commercial positions in high-growth markets.

Operating three production facilities in Denmark and Australia – including the largest facility in Europe – LGP is the one of the top three suppliers in Australia, the largest supplier into France, and a significant supplier into Germany and the UK, positioning it as a key player in global medicinal cannabis markets.

With diversified revenue streams, a presence in over a dozen export markets, and a high net tangible asset position relative to its enterprise value, LGP offers investors leveraged exposure to global medicinal cannabis demand and a clear platform for scalable growth.

For more information about Little Green Pharma go to: [www.littlegreenpharma.com](http://www.littlegreenpharma.com) and Reset Mind Sciences: <https://www.resetmind.com.au/>

## Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email to help reduce our costs and environmental footprint:

To easily update your communication preferences, visit: [www.investorcentre.com/au](http://www.investorcentre.com/au)

## LGP's Cannabis Wrap

LGP's Cannabis Wrap offers insights on global cannabis markets with links to key news and developments from around the world

Sign up to LGP's Cannabis Wrap here: <https://investlittlegreenpharma.com/site/contact/newsletter-sign-up>

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*  
Introduced 30/9/2001.

<b>Name of entity</b>	Little Green Pharma Ltd
<b>ACN</b>	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Michael David Lynch-Bell
<b>Date of last notice</b>	4 April 2024

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
<b>Date of change</b>	15 July 2025
<b>No. of securities held prior to change</b>	(a) 1,758,450 Ordinary shares (b) 70,000 Retention Share Rights vesting 20 Feb 25, expiring 20 Feb 26 (c) 140,000 Retention Share Rights vesting 20 Feb 26, expiring 20 Feb 28 (d) 300,000 Retention Share Rights vesting 31 Mar 27,expiring on 31 Mar 29
<b>Class</b>	(a) Ordinary shares (b) Retention Share Rights vesting 20 Feb 25, expiring 20 Feb 26
<b>Number acquired</b>	(a) 70,000 Ordinary shares
<b>Number disposed</b>	(b) 70,000 Retention Share Rights vesting 20 Feb 25, expiring 20 Feb 26
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil - shares issued on exercise of vested retention share rights

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>	(a) 1,828,450 Ordinary shares (b) Nil (c) 140,000 Retention Share Rights vesting 20 Feb 26, expiring 20 Feb 28 (d) 300,000 Retention Share Rights vesting 31 Mar 27, expiring on 31 Mar 29
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of vested retention share rights

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

### Part 3 – +Closed period

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	Little Green Pharma Ltd
<b>ACN</b>	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Neale William Fong
<b>Date of last notice</b>	4 April 2024

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Riverpalm Pty Ltd ATF NW Fong Family Trust - Dr Fong is a director and beneficiary of the trust  Dr Neale Fong ATF Damblock Trust - Dr Fong is a trustee and beneficiary of the trust
<b>Date of change</b>	15 July 2025
<b>No. of securities held prior to change</b>	Riverpalm Pty Ltd <NW Fong Family Trust> (a) 296,154 Ordinary shares  Dr Neale Fong <Damblock Trust> (a) 1,254,575 Ordinary shares (b) 35,000 Retention Share Rights vesting 20 Feb 25, expiring 20 Feb 26 (c) 70,000 Retention Share Rights vesting 20 Feb 26, expiring 20 Feb 28 (d) 150,000 Retention Share Rights vesting 31 Mar 27, expiring 31 Mar 29
<b>Class</b>	(a) Ordinary shares (b) Retention Share Rights vesting 20 Feb 25, expiring 20 Feb 26
<b>Number acquired</b>	(a) 35,000 Ordinary shares
<b>Number disposed</b>	(b) 35,000 Retention Share Rights vesting 20 Feb 25, expiring 20 Feb 26

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil - shares issued on exercise of vested retention share rights
<b>No. of securities held after change</b>	Riverpalm Pty Ltd <NW Fong Family Trust> (a) 296,154 Ordinary shares  Dr Neale Fong <Damblock Trust> (a) 1,289,575 Ordinary shares (b) Nil (c) 70,000 Retention Share Rights vesting 20 Feb 26, expiring 20 Feb 28 (d) 150,000 Retention Share Rights vesting 31 Mar 27, expiring 31 Mar 29
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of vested retention share rights

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

### Part 3 – +Closed period

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.